• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Rezolute Inc (NQ: RZLT )

    3.280 +0.310 (+10.43%)
    Streaming Delayed Price Updated: 10:47 AM EDT, May 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 71,366
    Open 2.980
    Bid (Size) 3.200 (1)
    Ask (Size) 3.280 (1)
    Prev. Close 2.970
    Today's Range 2.980 - 3.290
    52wk Range 0.7200 - 3.690
    Shares Outstanding 39,625,271
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
    From Rezolute, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +223.13%
    +223.13%
    1 Month
    +43.22%
    +43.22%
    3 Month
    +231.29%
    +231.29%
    6 Month
    +234.67%
    +234.67%
    1 Year
    +52.55%
    +52.55%

    More News

    Read More
    Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
    Via InvestorPlace
    Rezolute Inc. (NASDAQ: RZLT) Climbs to New 52-Week High
    Via Investor Brand Network
    CommScope Holding And 2 Other Stocks Under $3 Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Analyst Expectations for Rezolute's Future
    Via Benzinga
    Expert Ratings for Rezolute
    Via Benzinga
    3 Stocks Insiders Are Buying That Analysts Love
    Via MarketBeat
    $17M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    $1.5M Bet On This Penny Stock? Check Out These 4 Stocks Under $5 Insiders Are Aggressively Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
    From Rezolute, Inc.
    Via GlobeNewswire
    Lumen Technologies And 3 Other Stocks Under $3 Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Rezolute And 3 Other Penny Stocks Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
    From Rezolute, Inc.
    Via GlobeNewswire
    Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
    From Rezolute, Inc.
    Via GlobeNewswire
    Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
    From Rezolute, Inc.
    Via GlobeNewswire
    Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
    From Rezolute, Inc.
    Via GlobeNewswire
    Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"
    Via Newsfile
    Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
    From Rezolute, Inc.
    Via GlobeNewswire
    Rezolute Reports First Quarter Fiscal 2024 Results
    From Rezolute, Inc.
    Via GlobeNewswire
    Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
    From Rezolute, Inc.
    Via GlobeNewswire
    Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
    From Rezolute, Inc.
    Via GlobeNewswire
    Stocks That Hit 52-Week Lows On Monday
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.